Custom In Vivo Tumor Model Services

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

KP (KP1 / KP4) Syngeneic Model Service for Lung Cancer

Fig 1: KP (KP1 / KP4) Syngeneic Model for Lung Cancer preclinical research.

The KP (KP1 / KP4) syngeneic model service for lung cancer is an immune-competent C57BL/6 platform built on tumor-derived lines from the KrasG12D;Trp53 conditionally null (KP) genetically engineered mouse model — the gold-standard lung adenocarcinoma genotype — supporting flank-efficacy, orthotopic, and checkpoint-combination study designs. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated KP1 / KP4 expansion and banking, subcutaneous or intrapulmonary implantation, scheduled caliper or micro-CT monitoring, and full adenocarcinoma histopathology with tumor-microenvironment profiling — all configured around each sponsor’s Kras-pathway, checkpoint, or combination-therapy hypothesis.

Overview of KP (KP1 / KP4) Syngeneic Model for Lung Cancer

The KP designation refers to the most consequential genotype in lung adenocarcinoma modeling: KrasG12D activation combined with Trp53 deletion, engineered conditionally in C57BL/6 mice (Jackson Laboratory strain 032435) and induced in the lung epithelium by intratracheal or intranasal adenoviral Cre delivery — a system that recapitulates the stepwise progression from adenoma to invasive adenocarcinoma and remains the reference genetic framework for KRAS-driven human lung cancer. From these autochthonous tumors, cell lines can be established that retain the engineered genotype and grow in fully immunocompetent syngeneic C57BL/6 hosts; the lines designated KP1 and KP4 in the preclinical CRO literature (also listed as KP1-lung and KP4-lung) belong to this family, as do published relatives such as the independently characterized KP1–3 lines and KPL86. Documented characterization of KP-family lines confirms the expected KrasG12D recombination and Trp53 loss, anchorage-independent growth, and a molecular posture of high HMGA2 with low NKX2.1 that tracks with aggressive in vivo behavior.

Fig 2: Reference figures for KP (KP1 / KP4) cell-related literature. Fig 1. PKCι-dependent tumor trajectory model of the KP syngeneic lung cancer system. (Nguyen, Duy T., et al., 2025)

What distinguishes the KP syngeneic system is its translational wiring. Because the driver lesion is the same KrasG12D found in human lung adenocarcinoma, the platform has served the targeted-therapy era directly: autochthonous KP tumors — which activate CDK4 signaling in their p53-null state — respond to the CDK4/6 inhibitor palbociclib, and concomitant CDK4 plus MAPK-pathway blockade (palbociclib with the MEK inhibitor AZD6244) augments response in Kras-mutant tumors, establishing the therapeutic logic now pursued in the clinic. As a transplantable syngeneic system, KP lines support both flank grafts for rapid efficacy screening and intrapulmonary orthotopic implantation — the format that best preserves lung microenvironmental context for tumor-host interaction and immunotherapy studies, with interferon-γ inducible PD-L1 expression providing a mechanistic bridge to checkpoint sensitivity. For sponsors, KP1/KP4 thus offer the rare combination of a bona fide oncogene-defined lung adenocarcinoma genotype, immune-competent C57BL/6 hosting, orthotopic capability, and a benchmarked targeted-therapy rationale in a single platform.

Cell Line Information: KP (KP1 / KP4)

The table below consolidates the key biological, genetic, and modeling characteristics of the KP-derived syngeneic lines, cross-referenced with the parental genetically engineered model.

Parameter	Details
Cell line designation	KP1 and KP4 (listed in the preclinical CRO literature as KP1-lung and KP4-lung); members of the tumor-derived line family from the KP genetically engineered mouse model, alongside published relatives such as KP1–3 and KPL86
Species / genetic background	Mouse (Mus musculus), C57BL/6 inbred background; syngeneic in C57BL/6 immunocompetent hosts
Parental model	KrasLSL-G12D;Trp53fl/fl conditional mice (Jackson Laboratory strain 032435); lung tumors initiated by intratracheal or intranasal adenoviral Cre recombinase (published protocols use Ad-CMV-Cre at approximately 1.5 × 10⁸ PFU/mL)
Genotype	KrasG12D oncogenic activation with Trp53 deletion in the tumor cells; recombination of the conditional alleles is verifiable by genomic PCR — the standard authentication step for KP-family lines
Documented characterization of KP-family lines	Complete LSL-KrasG12D and Trp53fl recombination confirmed by PCR in independently derived KP lines; anchorage-independent soft-agar growth and oncosphere formation; high HMGA2 and low NKX2.1 expression tracking with aggressive in vivo behavior; interferon-γ-inducible PD-L1 expression linking to checkpoint responsiveness
Tumor type	Murine lung adenocarcinoma (NSCLC), Kras-driven
Growth properties	Adherent epithelial-like tumor cells; robust proliferation in standard complete medium with reliable syngeneic take; orthotopic intrapulmonary growth in immunocompetent C57BL/6 hosts per published ≥75% take-rate criteria
Recommended culture conditions	DMEM (high glucose with L-glutamine and sodium pyruvate) supplemented with 10% fetal bovine serum at 37 °C in a humidified 5% CO₂ atmosphere, as used across the published C57BL/6 orthotopic line methodology; mycoplasma testing before in vivo use
Standard implantation practice	Flank: approximately 5 × 10⁵ cells in a 50% HBSS/50% Matrigel suspension for syngeneic efficacy studies; orthotopic: approximately 2.5 × 10⁵ cells in 40 μL into the left lung through a surgical approach, with micro-CT monitoring documented for response assessment
*Documented in vivo* therapeutic responses**	Autochthonous KrasG12D;Trp53-null lung tumors respond to CDK4/6 inhibition (palbociclib), with augmented response when MAPK-pathway blockade (AZD6244) is added concomitantly — the combination rationale benchmarked on the KP genotype; orthotopic C57BL/6 platforms of this class support anti-PD-1 sensitivity profiling via interferon-γ-inducible PD-L1
Host strains	C57BL/6 immunocompetent mice (syngeneic); knockout and reporter variants used for mechanism studies
Key research applications	KrasG12D-targeted therapy and MEK/CDK4-combination evaluation; checkpoint immunotherapy in an oncogene-defined lung adenocarcinoma; orthotopic-versus-flank microenvironment comparison; tumor-immune microenvironment dissection; imaging-tracked (micro-CT, bioluminescence) response studies; GEMM-to-syngeneic translational bridging

Our Services

An oncogene-defined lung platform earns its keep only when genotype authentication and microenvironment fidelity are both enforced, and Alfa Cytology runs the KP (KP1 / KP4) program to that standard: conditional-allele recombination verified by genomic PCR, validated flank and intrapulmonary formats, scheduled caliper or micro-CT monitoring, and endpoint pathology with Kras-pathway pharmacodynamics — all under one accountable preclinical operation.

Workflow of KP (KP1 / KP4) Syngeneic Model Construction

Construction follows the published C57BL/6 orthotopic-line methodology: KP1 / KP4 cells are expanded under authenticated conditions, implanted subcutaneously or intrapulmonarily into C57BL/6 mice, grown to a standardized baseline, randomized, treated, and analyzed with efficacy and microenvironment endpoints. The workflow comprises the following stages.

Cell authentication and banking: KP1 / KP4 cells are mycoplasma-tested, identity-verified, and confirmed for KrasG12D;Trp53 recombination by genomic PCR — the defining quality step for the platform — then expanded into low-passage working banks.
Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at approximately 5 × 10⁵ cells (flank, in 50% HBSS/50% Matrigel) or 2.5 × 10⁵ cells in 40 μL (orthotopic) per validated protocol.
Anesthesia and implantation: C57BL/6 mice are anesthetized with isoflurane; cells are implanted subcutaneously into the flank, or injected into the left lung through a brief surgical exposure with a fine-gauge needle, per the study arm.
Establishment monitoring and randomization: Flank tumors are measured by caliper from first palpability; orthotopic burden is tracked by scheduled micro-CT where available; animals are randomized once tumors reach the protocol-specified baseline, balancing groups.
Treatment administration: Experimental arms — MEK and CDK4/6 inhibitors alone and combined, Kras-pathway agents, checkpoint inhibitors, and radiotherapy or combination regimens — proceed per study design with body-weight and toxicity monitoring.
Imaging and interim measurements: Caliper measurements or serial micro-CT sessions track tumor kinetics; reporter-arm studies support bioluminescence-based burden quantification on a scheduled cadence.
Endpoint and histopathological analysis: Endpoints integrate tumor-growth inhibition and survival with histopathology (H&E confirming lung adenocarcinoma histology, plus Ki67, phospho-ERK/phospho-RB pathway staining, CD8, and PD-L1 immunohistochemistry) and tumor-immune-microenvironment profiling by flow cytometry or spatial methods where designs require it.

Fig 3: Workflow for the establishment of KP (KP1 / KP4) Syngeneic Models. Fig 2. KP (KP1 / KP4) Syngeneic Model construction workflow.

Case Study-KP (KP1 / KP4) Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the KP (KP1 / KP4) platform spanning MEK/CDK4-combination evaluation, checkpoint immunotherapy assessment, and orthotopic microenvironment studies in Kras-driven lung adenocarcinoma. In these studies, implanted KP tumors were monitored through scheduled caliper or imaging measurements, treated per randomized regimens, and characterized at endpoint by histopathology with Kras-pathway pharmacodynamic staining and immune-microenvironment profiling. Study-level datasets are available upon request.

Fig 4: Case Study-KP (KP1 / KP4) Syngeneic Model Development.

Why Choose Alfa Cytology?

Alfa Cytology pairs GEMM-derived-line operational experience with genotype-authentication discipline, so every KP (KP1 / KP4) study is executed with verified KrasG12D;Trp53 status, validated orthotopic and flank formats, and reporting that reflects the platform’s targeted-therapy logic.

Focused experience with oncogene-defined C57BL/6 lung platforms, including conditional-allele recombination verification by genomic PCR.
A single coordinated team managing cell banking, flank and intrapulmonary implantation, micro-CT monitoring, and endpoint pathology under one quality framework.
Design fluency with MEK/CDK4 combinations, checkpoint regimens, and orthotopic microenvironment studies.
Endpoint panels pairing adenocarcinoma histology with phospho-ERK/phospho-RB pharmacodynamics and PD-L1 immunohistochemistry.
Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your lung cancer program targets the KrasG12D;Trp53-null genotype with pathway inhibitors, checkpoint combinations, or orthotopic study designs, Alfa Cytology is ready to build the study around your hypothesis. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the KP (KP1 / KP4) syngeneic model service.

Reference

Nguyen, Duy T., et al. "Protein kinase Cι dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma." Cell reports 44.12 (2025).

For research use only. Not intended for any clinical use.